Nanobiotix S.A. (NBTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Nanobiotix S.A. (NBTX) closed at USD 21.28 on 2026-10-14, a change of +20.7 % over the past year, with a market capitalization of USD 1.13B.

Nanobiotix S.A. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Nanobiotix S.A. key figures

Previous close

USD 21.28 (2026-10-14)

1-year change

+20.7 %

Market cap

USD 1.13B

Enterprise value

USD 1.13B

P/E ratio (trailing)

-16.71

P/E ratio (forward)

-133.00

EPS (trailing)

-1.33

EPS (forward)

-0.17

PEG ratio

n/a

Price to book

-30.22

Revenue growth

-79.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.10

Employees

98

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Nanobiotix S.A.

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Nanobiotix S.A. and compare it with other stocks.